{"id":"placebo-for-valsartan","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance used as a control in clinical trials to establish the efficacy of an active drug by comparison. It relies on the placebo effect—the psychological and physiological response to the expectation of treatment—rather than any direct molecular mechanism. In the context of Valsartan trials, placebo serves as the comparator arm to demonstrate that Valsartan's blood pressure-lowering effects are due to its pharmacological action, not expectation alone.","oneSentence":"A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:02.801Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in clinical trials for hypertension and related cardiovascular conditions"}]},"trialDetails":[{"nctId":"NCT04649229","phase":"PHASE4","title":"Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3","status":"COMPLETED","sponsor":"Yale University","startDate":"2021-05-27","conditions":"Heart Failure","enrollment":46},{"nctId":"NCT04153136","phase":"PHASE2","title":"The ENCHANTMENT HIV Study","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2020-09-11","conditions":"HIV/AIDS, Heart Failure With Preserved Ejection Fraction","enrollment":39},{"nctId":"NCT06930885","phase":"PHASE3","title":"Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease","status":"RECRUITING","sponsor":"Hospital do Coracao","startDate":"2025-06-12","conditions":"Atherothrombotic Diseases, Atherosclerotic Cardiovascular Disease (ASCVD)","enrollment":7713},{"nctId":"NCT06237309","phase":"PHASE2","title":"REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-04-11","conditions":"Heart Failure","enrollment":89},{"nctId":"NCT05056727","phase":"PHASE3","title":"A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-09-30","conditions":"Renal Insufficiency, Chronic, Hyperkalemia","enrollment":1112},{"nctId":"NCT05764057","phase":"PHASE3","title":"DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-06-12","conditions":"AMI, STEMI, NSTEMI","enrollment":450},{"nctId":"NCT05498181","phase":"PHASE2","title":"Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-10-11","conditions":"Hemodialysis","enrollment":100},{"nctId":"NCT06693674","phase":"PHASE3","title":"Effect of Sacubitril-Valsartan on Cardiac Structure and Function","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-02-03","conditions":"Congenital Heart Disease","enrollment":45},{"nctId":"NCT04113109","phase":"PHASE4","title":"Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2019-11-01","conditions":"Heart Failure","enrollment":46},{"nctId":"NCT03938389","phase":"PHASE4","title":"The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University","startDate":"2020-02-25","conditions":"PreDiabetes, Impaired Glucose Tolerance, Obesity","enrollment":90},{"nctId":"NCT05920005","phase":"PHASE3","title":"Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2023-08-22","conditions":"Hypertension","enrollment":702},{"nctId":"NCT03686657","phase":"PHASE1, PHASE2","title":"Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients","status":"NOT_YET_RECRUITING","sponsor":"ARKAY Therapeutics","startDate":"2025-10-10","conditions":"Type 2 Diabetes, High Blood Pressure, Arthritis","enrollment":115},{"nctId":"NCT04971720","phase":"PHASE2, PHASE3","title":"PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2022-02-18","conditions":"Obesity, Cardiovascular Diseases, Hypertension","enrollment":160},{"nctId":"NCT06053580","phase":"PHASE2","title":"Repurposing Valsartan May Protect Against Pulmonary Hypertension","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-02-28","conditions":"Pulmonary Arterial Hypertension, Right Heart Failure, Right Ventricular Dysfunction","enrollment":60},{"nctId":"NCT05465031","phase":"PHASE4","title":"Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)","status":"RECRUITING","sponsor":"Silesian Centre for Heart Diseases","startDate":"2024-04-17","conditions":"Breast Cancer, Neoplasm, Breast, Breast Diseases","enrollment":600},{"nctId":"NCT06863987","phase":"PHASE3","title":"A Phase III Clinical Study of Valsartan Oral Solution for the Treatment of Hypertension in Children and Adolescents","status":"ENROLLING_BY_INVITATION","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2025-02-05","conditions":"Essential Hypertension","enrollment":342},{"nctId":"NCT05593575","phase":"PHASE2","title":"Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease","status":"COMPLETED","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","startDate":"2023-03-22","conditions":"Diabetic Kidney Disease","enrollment":305},{"nctId":"NCT03760588","phase":"PHASE2","title":"Prevention of Cardiac Dysfunction During Breast Cancer Therapy","status":"COMPLETED","sponsor":"Torbjorn Omland","startDate":"2019-01-31","conditions":"Breast Cancer Female, Heart Failure","enrollment":138},{"nctId":"NCT04149990","phase":"PHASE2","title":"Angiotensin-Neprilysin Inhibition in Diastolic Dysfunction After AMI","status":"TERMINATED","sponsor":"Jacob Moller","startDate":"2018-10-12","conditions":"Myocardial Infarction, Diastolic Dysfunction","enrollment":51},{"nctId":"NCT05155137","phase":"PHASE3","title":"Polypill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt (PROMOTE)","status":"RECRUITING","sponsor":"Hospital Moinhos de Vento","startDate":"2021-12-20","conditions":"Stroke, Cognitive Decline","enrollment":8518},{"nctId":"NCT06771245","phase":"PHASE3","title":"A Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets In Hypertensive Patients","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2025-01-24","conditions":"Mild-to-moderate Essential Hypertension","enrollment":606},{"nctId":"NCT06716970","phase":"PHASE3","title":"QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Wuhan Createrna Science and Technology Co., Ltd","startDate":"2024-12-30","conditions":"Essential Hypertension","enrollment":810},{"nctId":"NCT05508035","phase":"PHASE3","title":"The Effect of Sacubitril/valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients with Ischemic Heart Failure with Mid-range Ejection Fraction","status":"RECRUITING","sponsor":"John Paul II Hospital, Krakow","startDate":"2023-07-13","conditions":"Heart Failure with Moderately Reduced Ejection Fraction","enrollment":666},{"nctId":"NCT02884206","phase":"PHASE3","title":"Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-11-23","conditions":"Chronic Heart Failure (CHF)","enrollment":592},{"nctId":"NCT04883528","phase":"PHASE1, PHASE2","title":"Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019","status":"COMPLETED","sponsor":"Duke University","startDate":"2021-08-06","conditions":"Covid19","enrollment":42},{"nctId":"NCT04707261","phase":"PHASE4","title":"Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)","status":"RECRUITING","sponsor":"Xiangtan Central Hospital","startDate":"2021-08-06","conditions":"Anemia, Heart Failure","enrollment":1990},{"nctId":"NCT05359068","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension","status":"COMPLETED","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","startDate":"2021-06-10","conditions":"Essential Hypertension","enrollment":957},{"nctId":"NCT05117736","phase":"NA","title":"ARNI Versus plAcebo in Patients With Congenital sYStemic Right Ventricle Heart Failure","status":"TERMINATED","sponsor":"Montreal Heart Institute","startDate":"2022-03-15","conditions":"Systemic Right Ventricle, Heart Failure","enrollment":15},{"nctId":"NCT03917459","phase":"PHASE3","title":"COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-04-16","conditions":"Heart Failure, Heart Failure, Systolic, Erectile Dysfunction","enrollment":27},{"nctId":"NCT02468232","phase":"PHASE3","title":"Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-06-15","conditions":"Heart Failure With Reduced Ejection Fraction (HF-rEF)","enrollment":225},{"nctId":"NCT00097786","phase":"PHASE3","title":"Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2002-01","conditions":"Diabetes Mellitus, Type 2","enrollment":9306},{"nctId":"NCT00241098","phase":"PHASE4","title":"The VALIDATE Study of Valsartan for Patients With Early Stage Heart Failure","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-05","conditions":"Hypertension, Congestive Heart Failure","enrollment":37},{"nctId":"NCT02924727","phase":"PHASE3","title":"Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-12-09","conditions":"Acute Myocardial Infarction","enrollment":5669},{"nctId":"NCT05487261","phase":"PHASE4","title":"Pulmonary REsistance Modification Under Treatment With Sacubitril/valsartaN in paTients With Heart Failure With Reduced Ejection Fraction","status":"UNKNOWN","sponsor":"Clinical Hospital Heliodor Swiecicki of the Medical University of Karol Marcinkowski in Poznań","startDate":"2022-12-13","conditions":"Heart Failure","enrollment":260},{"nctId":"NCT03315832","phase":"PHASE2, PHASE3","title":"Efficacy of Angiotensin Receptor Blocker Following aortIc Valve Intervention for Aortic STenOsis: a Randomized mulTi-cEntric Double-blind Phase II Study","status":"WITHDRAWN","sponsor":"University Hospital, Limoges","startDate":"2023-01-02","conditions":"Aortic Valve Stenosis, Valsartan, Angiotensin Receptor Antagonists","enrollment":""},{"nctId":"NCT02678312","phase":"PHASE2, PHASE3","title":"Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-11-03","conditions":"Pediatric Heart Failure","enrollment":393},{"nctId":"NCT04394117","phase":"PHASE4","title":"Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease","status":"COMPLETED","sponsor":"The George Institute","startDate":"2020-06-19","conditions":"Coronavirus Disease 2019, COVID-19","enrollment":787},{"nctId":"NCT02130687","phase":"NA","title":"Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2014-06","conditions":"Type 2 Diabetes Mellitus, Hypertension","enrollment":106},{"nctId":"NCT02816736","phase":"PHASE4","title":"EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-03-02","conditions":"Heart Failure","enrollment":365},{"nctId":"NCT05089539","phase":"PHASE2","title":"The Effect of Angiotensin Receptor-Neprilysin Inhibition on Cardiac Fibrosis in Patients With HFpEF","status":"UNKNOWN","sponsor":"Chongqing Medical University","startDate":"2021-11-01","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":60},{"nctId":"NCT03066804","phase":"PHASE3","title":"A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-08-22","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":2572},{"nctId":"NCT02768298","phase":"PHASE4","title":"Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-07-12","conditions":"Chronic Heart Failure With Reduced Ejection Fraction","enrollment":201},{"nctId":"NCT02970669","phase":"PHASE4","title":"Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-12-16","conditions":"Heart Failure, Reduced Ejection Fraction","enrollment":140},{"nctId":"NCT04335786","phase":"PHASE4","title":"Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2020-04-17","conditions":"Acute Respiratory Distress Syndrome, SARS-CoV-2, COVID","enrollment":23},{"nctId":"NCT01912534","phase":"PHASE2","title":"Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM","status":"COMPLETED","sponsor":"Carelon Research","startDate":"2014-03","conditions":"Hypertrophic Cardiomyopathy","enrollment":211},{"nctId":"NCT02874794","phase":"PHASE4","title":"Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-08-17","conditions":"Heart Failure and Reduced Ejection Fraction","enrollment":465},{"nctId":"NCT01870739","phase":"PHASE2","title":"A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-10","conditions":"Hypertension","enrollment":115},{"nctId":"NCT02554890","phase":"PHASE4","title":"Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-04-29","conditions":"Acute Heart Failure","enrollment":887},{"nctId":"NCT02900378","phase":"PHASE3","title":"randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-12-20","conditions":"Chronic Heart Failure With Reduced Ejection Fraction","enrollment":621},{"nctId":"NCT02788656","phase":"PHASE4","title":"Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2016-09","conditions":"Congestive Heart Failure","enrollment":4},{"nctId":"NCT02636283","phase":"PHASE2","title":"Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease","status":"TERMINATED","sponsor":"University of Minnesota","startDate":"2017-12-31","conditions":"Peripheral Arterial Disease","enrollment":6},{"nctId":"NCT03791723","phase":"NA","title":"Effect of ARNI in Patients With Persistent AF and Enlarged Left Atrium After Catheter Ablation","status":"UNKNOWN","sponsor":"The Second Affiliated Hospital of Chongqing Medical University","startDate":"2019-06-01","conditions":"Atrial Fibrillation, Cardiac Remodeling, Atrial, Sacubitril/Valsartan","enrollment":90},{"nctId":"NCT02480764","phase":"PHASE3","title":"Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-08-27","conditions":"Essential Hypertension","enrollment":612},{"nctId":"NCT02606279","phase":"NA","title":"Angiotensin Receptors and Age Related Mitochondrial Decline in HIV Patients","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2014-07","conditions":"HIV, Aging, Sarcopenia","enrollment":1},{"nctId":"NCT02639637","phase":"PHASE4","title":"Effect of DPP4 Inhibition on Vasoconstriction","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2015-12","conditions":"Type 2 Diabetes Mellitus","enrollment":18},{"nctId":"NCT02572960","phase":"PHASE4","title":"Physiologic Interactions Between the Adrenal- and the Parathyroid Glands","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2015-10","conditions":"Osteoporosis, Vitamin D Deficiency, Cardiovascular Disease","enrollment":81},{"nctId":"NCT01252238","phase":"NA","title":"Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2010-06","conditions":"Insulin Sensitivity, Aortic Compliance, Diastolic Function","enrollment":24},{"nctId":"NCT01318395","phase":"PHASE3","title":"Aliskiren on Retinal Vasculature Treatment Study","status":"COMPLETED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2010-05","conditions":"Arterial Hypertension","enrollment":56},{"nctId":"NCT03005184","phase":"PHASE2","title":"Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2","status":"WITHDRAWN","sponsor":"Vanderbilt University Medical Center","startDate":"2017-09","conditions":"Heart Failure NYHA Class I, Heart Failure NYHA Class II, Heart Failure NYHA Class III","enrollment":""},{"nctId":"NCT03393377","phase":"NA","title":"Preventive Arterial Wall Phenotype and Low-dose Fluvastatin/Valsartan Combination","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2014-09","conditions":"Atherosclerosis","enrollment":20},{"nctId":"NCT00168779","phase":"PHASE4","title":"Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-09","conditions":"Hypertension","enrollment":1185},{"nctId":"NCT03309618","phase":"NA","title":"Post- Myocardial Infarction Arterial Wall Improvement by Low-dose Fluvastatin and Valsartan","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2012-11","conditions":"Myocardial Infarction","enrollment":36},{"nctId":"NCT01617681","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-11-08","conditions":"Pediatric Hypertension With or Without CKD","enrollment":127},{"nctId":"NCT02495324","phase":"PHASE4","title":"Fimasartan Achieving SBP Target (FAST) Study","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2015-06","conditions":"Essential,Hypertension","enrollment":369},{"nctId":"NCT01785472","phase":"PHASE3","title":"Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-04","conditions":"Essential Hypertension","enrollment":1438},{"nctId":"NCT01377285","phase":"PHASE4","title":"Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD)","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2010-06","conditions":"Chronic Renal Failure","enrollment":350},{"nctId":"NCT01672476","phase":"PHASE3","title":"A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2012-04","conditions":"Hypertension","enrollment":293},{"nctId":"NCT01400256","phase":"PHASE4","title":"Blood Pressure Lowering in Acute Stroke Trial","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2007-08","conditions":"Stroke, Acute","enrollment":""},{"nctId":"NCT01692301","phase":"PHASE2","title":"Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12","conditions":"Hypertension","enrollment":454},{"nctId":"NCT00878969","phase":"PHASE3","title":"Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3","status":"TERMINATED","sponsor":"Vanderbilt University","startDate":"2010-01","conditions":"Oxidative Stress, Endothelial Dysfunction","enrollment":78},{"nctId":"NCT01193101","phase":"PHASE2","title":"Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-08","conditions":"Hypertension","enrollment":389},{"nctId":"NCT01281306","phase":"PHASE2","title":"An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-01","conditions":"Systolic Hypertension","enrollment":910},{"nctId":"NCT01876368","phase":"PHASE3","title":"Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-09","conditions":"Hypertension","enrollment":376},{"nctId":"NCT01663233","phase":"PHASE3","title":"Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-08","conditions":"Essential Hypertension","enrollment":266},{"nctId":"NCT01615198","phase":"PHASE3","title":"Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-08","conditions":"Essential Hypertension","enrollment":588},{"nctId":"NCT01599104","phase":"PHASE3","title":"Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-06","conditions":"Essential Hypertension","enrollment":1161},{"nctId":"NCT00549770","phase":"PHASE2","title":"Efficacy and Safety of LCZ696A in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-09","conditions":"Hypertension","enrollment":1334},{"nctId":"NCT00887588","phase":"PHASE2","title":"LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-11","conditions":"Chronic Heart Failure","enrollment":307},{"nctId":"NCT01631864","phase":"PHASE2","title":"Evaluation of the Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-10","conditions":"Hypertension, Concurrent Obesity","enrollment":98},{"nctId":"NCT00089518","phase":"PHASE3","title":"Optimal Treatment for Kidney Disease in HIV Infected Adults","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Kidney Disease","enrollment":""},{"nctId":"NCT01918332","phase":"PHASE3","title":"Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2012-04","conditions":"Hypertension,, Hyperlipidemia","enrollment":168},{"nctId":"NCT00437645","phase":"PHASE3","title":"Efficacy and Safety of Valsartan/Amlodipine Compared to Amlodipine in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-01","conditions":"Essential Hypertension","enrollment":1183},{"nctId":"NCT01699490","phase":"PHASE4","title":"Role of Inflammation Factors and Insulin Resistance in Major Depressive Disorder","status":"UNKNOWN","sponsor":"National Cheng-Kung University Hospital","startDate":"2012-08","conditions":"Major Depressive Disorder","enrollment":200},{"nctId":"NCT02242318","phase":"PHASE4","title":"Study to Evaluate Efficacy of Micardis® (Telmisartan) and Valsartan in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure Monitoring","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2001-09","conditions":"Hypertension","enrollment":440},{"nctId":"NCT01865188","phase":"PHASE3","title":"Study of the Efficacy and Safety of LCZ696 Alone and in Combination With Amlodipine in Patients With Hypertension","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2014-04","conditions":"Hypertension","enrollment":""},{"nctId":"NCT01508026","phase":"PHASE3","title":"Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2012-01","conditions":"Stage 1 Hypertension, Stage 2 Hypertension","enrollment":4161},{"nctId":"NCT01992796","phase":"PHASE3","title":"Angiotensin II Antagonist in Severe Sepsis","status":"UNKNOWN","sponsor":"University of Salerno","startDate":"2014-01","conditions":"Severe Sepsis","enrollment":300},{"nctId":"NCT00732069","phase":"PHASE2","title":"Study of Inflammation and Oxidative Stress in Persons Undergoing Dialysis","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2008-08","conditions":"End Stage Renal Failure on Dialysis, Complication of Hemodialysis","enrollment":19},{"nctId":"NCT01368536","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-05","conditions":"Hypertension, Stage 2 Hypertension, Diabetes","enrollment":975},{"nctId":"NCT00927394","phase":"PHASE4","title":"Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-05","conditions":"Hypertension","enrollment":1143},{"nctId":"NCT00446511","phase":"PHASE3","title":"Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-06","conditions":"Hypertension","enrollment":250},{"nctId":"NCT00819767","phase":"PHASE2","title":"Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During Exercise","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-02","conditions":"Hypertension","enrollment":68},{"nctId":"NCT01001572","phase":"PHASE3","title":"Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-09","conditions":"Essential Hypertension","enrollment":932},{"nctId":"NCT00409578","phase":"PHASE2","title":"Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-02","conditions":"Post Acute Coronary Syndrome, Myocardial Ischemia","enrollment":1101},{"nctId":"NCT00696436","phase":"PHASE3","title":"An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-04","conditions":"Hypertension","enrollment":1291}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":433,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo for Valsartan","genericName":"Placebo for Valsartan","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Valsartan is a small molecule that acts as a Type-1 angiotensin II receptor antagonist, used to treat conditions such as hypertension, heart failure with moderately reduced ejection fraction, and acute myocardial infarction. It is often compared to other treatments, including sacubitril/valsartan and enalapril, in clinical trials for conditions like acute heart failure and hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}